Advertisement

Topics

Genoptix, Inc. Company Profile

03:37 EDT 25th March 2019 | BioPortfolio

Genoptix is a leading specialized laboratory service provider focused on delivering personalized and comprehensive diagnostic services to its physician customers, community-based hematologists and oncologists. On the forefront of personalized diagnostic services, Genoptix's highly trained group of hematopathologists utilize sophisticated technology to provide integrated testing and actionable diagnostic reports. Its diagnostic services are designed to optimize the care of patients suffering from hematomalignancies, or cancers of the blood and bone marrow, including leukemia and lymphoma, and other forms of cancer. Founded in 1999, Genoptix is a member of the Nasdaq Global Select Market, the S&P SmallCap 600 Index and the Russell 2000 Index and is headquartered in Carlsbad, California. For more information, please visit www.genoptix.com.


News Articles [11 Associated News Articles listed on BioPortfolio]

NeoGenomics to buy Genoptix for $125m

Under the deal, Genoptix will also secure one million shares of NeoGenomics common stock. Located in Carlsbad of California, Genoptix is specialized in hematology and solid tumor testing The post Neo...

VCs buy commercial lab business of Genoptix from Novartis

Ampersand Capital and 1315 Capital have acquired Genoptix Inc. (clinical oncology diagnostics and informatics services) from Novartis AG for an undisclosed sum. The acquisition primarily includes Geno...

NeoGenomics Completes Acquisition of Genoptix

NeoGenomics (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services, announced today that it has completed the acquisition of the parent company of Genoptix for $125 million in ca...

NeoGenomics Buys Ex-Novartis Cancer Lab Genoptix for $125M, Stock

Cancer testing laboratory Genoptix is being acquired by NeoGenomics, another cancer-focused genetic testing business, for $125 million in cash and 1 million NeoGenomics shares. The buyout comes almost...

NeoGenomics buys Genoptix for $125mm cash plus stock

NeoGenomics Inc. signed a definitive agreement to acquire clinical cancer lab services firm Genoptix Inc. for $125mm in cash plus 1mm NeoGenomics shares (valued at $13.9mm based on the market average ...

M&As this week: NeoGenomics, Two Labs, Purdue Pharma

NeoGenomics has signed an agreement to buy Genoptix for $125m plus one million NeoGenomics common stock shares. Genoptix is a...Read More... The post M&As this week: NeoGenomics, Two Labs, Purdue...

Deals this week: NeoGenomics, Two Labs, Purdue Pharma

NeoGenomics has signed an agreement to buy Genoptix for $125m plus one million NeoGenomics common stock shares. Genoptix is a...Read More... The post Deals this week: NeoGenomics, Two Labs, Purdue Pha...

NeoGenomics to acquire Genoptix

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [2 Associated Companies listed on BioPortfolio]

Genoptix, Inc.

Genoptix is a leading specialized laboratory service provider focused on delivering personalized and comprehensive diagnostic services to its physician customers, community-based hematologists and onc...

Genoptix

Genoptix has developed a breadth of services that focus on the challenges of each phase of patient management to help in effective diagnosis, optimal treatment decisions and monitoring of hematopoieti...

More Information about "Genoptix, Inc." on BioPortfolio

We have published hundreds of Genoptix, Inc. news stories on BioPortfolio along with dozens of Genoptix, Inc. Clinical Trials and PubMed Articles about Genoptix, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Genoptix, Inc. Companies in our database. You can also find out about relevant Genoptix, Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Osteoporosis
Osteoporosis is a disease in which the bones become extremely porous, are subject to fracture, and heal slowly, occurring especially in women following menopause and often leading to curvature of the spine from vertebral collapse. Follow and track&n...


Corporate Database Quicklinks



Searches Linking to this Company Record